Kornimate/medical-research-clean huggingface dataset:
the effect of myofascial release exercises on viscoelastic changes of the pectoralis major muscle, pain, range of motion and shoulder functionality in individuals receiving adjuvant radiotherapy after breast cancer surgery

Conditions: Breast Cancer

Summary: chemotherapy, hormone therapy and radiotherapy used in the treatment of breast cancer try to prevent the recurrence of cancer. in addition to the benefits of radiotherapy, such as a decrease in recurrence and an increase in long-term survival, it may have side effects that may affect the well-being and daily life activities of patients. one of the treatment modalities used to cope with treatment-related side effects is myofascial release exercises. myofascial release exercises can help reduce adhesions caused by scar tissue and fibrosis caused by radiation. in the literature, there is no study investigating the effect of myofascial release exercises on pectoralis major muscle viscoelastic structure. for this purpose, our study aims to investigate the effect of myofascial release exercises performed in addition to home exercise programme on pectoralis major muscle viscoelastic structure, pain, range of motion and shoulder functionality.


Eligibility criteria:
inclusion criteria: * -stage i-ii-iii defined by radiation oncologists after breast cancer surgery and who will start radiotherapy * breast conserving surgery or total mastectomy with axillary lymph node dissection during surgery * no neurological or orthopaedic problems that may limit the range of motion of the shoulder joint in the preoperative evaluations, * individuals who volunteer to participate in the study will be included. exclusion criteria: * previous breast clamp surgery on the same side or contralateral side, * with a metastatic cancer focus, * post-surgical resistance, infection and open wound, pacemaker, * patients with a mini mental state examination test score of less than 21 will be excluded from the study.

Keywords: myofascial release exercises, breast cancer, radiotherapy
outcomes of rv dysfunction in acute exacerbation of chronic respiratory diseases

Conditions: Acute Exacerbation of COPD; Acute Exacerbation of Bronchiectasis; Acute Exacerbation of Asthma; Interstitial Lung Disease; Neuromuscular Diseases; Obesity Hypoventilation Syndrome; Acute Respiratory Failure

Summary: observational study in patients with chronic respiratory diseases (chronic obstructive pulmonary diseases, bronchiectasis, interstitial lung diseases, neuromuscular diseases, obesity-hypoventilation syndrome...) admitted in intensive care unit for acute respiratory failure. the main objective is to determine the prevalence of right ventricular (rv) dysfunction in this population and to analyze the impact of such a complication on outcomes (survival at day-28, duration of non-invasive or mechanical ventilation, duration of hospital stay). rv function will be assessed by echocardiography at admission, after 3 days and at discharge. plasma nt-probnp and troponin levels will be collected.

observational study in patients with chronic respiratory diseases (chronic obstructive pulmonary diseases, bronchiectasis, interstitial lung diseases, neuromuscular diseases, obesity-hypoventilation syndrome...) admitted in intensive care unit for acute respiratory failure. inclusion criteria: * chronic respiratory disease (copd, ild, ohs...) * admission in icu for acute respiratory failure * patient's non-opposition exclusion criteria: * patients \< 18 year-old * protected patients * pregnant women the main objective is to determine the prevalence of right ventricular (rv) dysfunction in this population and to analyze the impact of such a complication on outcomes (survival at day-28, duration of non-invasive or mechanical ventilation, duration of hospital stay). rv function will be assessed by echocardiography at admission, after 3 days and at discharge. plasma nt-probnp and troponin levels will be collected.

Eligibility criteria:
inclusion criteria: * chronic respiratory disease (copd, ild, ohs...) * admission in icu for acute respiratory failure * patient's non-opposition exclusion criteria: * patients \< 18 year-old * protected patients * pregnant women
renal denervation in chronic heart failure

Conditions: Heart Failure

Summary: renal denervation can be carried out for heart failure

there are theoretical reasons why renal denervation might be beneficial for patients with chronic heart failure. it is not known whether they would suffer large drops in blood pressure which might compromise safety. this pilot study required patients to remain in hospital for one week during which they had careful monitoring of blood pressure with the ability to halt the trial if any patient suffered any dangerous effect such as a large drop in blood pressure. it also monitored blood pressure after discharge for six months.

Eligibility criteria:
inclusion criteria: -patients were required to have chronic symptomatic systolic heart failure (nyha class iii or iv) on maximal tolerated medical therapy, including beta-blocker, ace inhibitor or angiotensin receptor blocker, and spironolactone. exclusion criteria: * clinically unstable patients or those with significant valvular disease * an estimated glomerular filtration rate \<35 ml/min * unfavourable renal anatomy * tortuous femoral arteries were not eligible
evaluation do early pars plana vitrectomy in acute endophthalmitis

Conditions: Endophthalmitis

Summary: our study will evaluate the efficacy of early ppv in acute endophthalmitis and attempt to prove its greater effectiveness for combating infection when compared to eyes that received only intravitreal antibiotic therapy

endophthalmitis, a severe inflammatory ocular condition with profound visual impairment that can lead to irreversible visual loss, requires immediate treatment. the only multicenter randomized trial of different forms of acute endophthalmitis treatment was the endophthalmitis vitrectomy study. the study concluded that intravitreal antibiotic injection improves visual prognosis, and pars plana vitrectomy (ppv) improves the final visual acuity (va) when performed in patients with light perception or worse va. our study will evaluate the efficacy of early ppv in acute endophthalmitis and attempt to prove its greater effectiveness for combating infection when compared to eyes that received only intravitreal antibiotic therapy. primary endpoint: the final va, ocular anatomy, retinal layer anatomy, and erg response in the intravitreal injection group will be compared with the ppv group. secondary endpoint: the final va, eyeball anatomy, retinal layer anatomy, and erg response in the group that underwent ppv will be compared with and without oral moxifloxacin therapy.

Eligibility criteria:
inclusion criteria: * patients with acute endophthalmitis with a history of ocular surgical procedures and a follow-up time of less than 6 weeks will be included. exclusion criteria: * patients with endophthalmitis lasting more than 6 weeks and no history of eye surgery will be excluded.
safety and efficacy of levomilnacipran er (levomilnacipran sr) in major depressive disorder

Conditions: Major Depressive Disorder

Summary: the purpose of this study is to evaluate the efficacy, safety, and tolerability of levomilnacipran er compared to placebo in patients with major depressive disorder (mdd).


Eligibility criteria:
inclusion criteria: * men and women, 18-75 years old * currently meet the dsm-iv-tr criteria for major depressive disorder * the patient's current depressive episode must be at least 6 weeks in duration exclusion criteria: * women who are pregnant, women who will be breastfeeding during the study, and women with childbearing potential who are not practicing a reliable method of birth control. * patients who are considered a suicide risk * patients with a history of meeting dsm-iv-tr criteria for * a. any manic or hypomanic episode * b. schizophrenia or any other psychotic disorder * c. obsessive-compulsive disorder.

Keywords: depression major depressive disorder
effect on shoulder training using rehabilitation robot for stroke patients

Conditions: Stroke

Summary: the purpose is to study the effect of rehabilitation robot on shoulder training for stroke patients.


Eligibility criteria:
inclusion criteria: * stroke (1-3 months) * brunnstrom stage ii-iii * single, unilateral exclusion criteria: * aphasic * shoulder impairment * severe osteoporosis
defining the operating parameters for a rebound-esthesiometer

Conditions: Corneal Sensation Reduced; Corneal Dystrophy; Corneal Degeneration; Corneal Transplant Failure; Herpetic Keratitis

Summary: the purpose of this study is to define the operating parameters for a new method to measure corneal sensitivity.

corneal sensitivity is the most important protective mechanism of the eye. thus, measuring it at any given time gives important indicators of corneal physiology, especially in the diagnostics of corneal and systemic diseases (e.g. diabetes, herpes simplex and keratitis) and recovery from ocular surgery. current commercial measurement methods are outdated, non-quantitative and uncomfortable to use, hence left unused. this results in suboptimal, even poor, diagnosis and treatment for patients. in this study the operating parameters for a state-of-the-art esthesiometer are defined. the operating principle is based on existing rebound technology which is already approved for iop measurement.

Eligibility criteria:
inclusion criteria: * age \>= 18 * informed consent signed exclusion criteria: * signs of infectious or inflammatory disease of anterior eye at the time of presentation. * during last two weeks, any of the following events or conditions occurred or was present: inflammatory or infectious ocular condition, surgical or other intervention or therapy, other abnormal ocular event. * unable to give informed consent. * directly or indirectly indicated vunerability.

Keywords: esthesiometry corneal sensitivity
anatomical variation in rouvière's sulcus

Conditions: Rouvière's Sulcus

Summary: rouvière's sulcus is a 2-5 cm fissure lying on the lower face of the liver, between the right lobe and caudate process. due to its extrabiliary location, rouvière's sulcus could be used as an anatomical landmark for safe laparoscopic cholecystectomy. in literature there's an high variability about rouvière sulcus prevalence and its anatomical variants.

the goal of this observational study is to evaluate the presence of rouvière sulcus in patients underwent laparoscopic cholecystectomy. the main questions it aims to answer are the prevalence and the anatomical variations of rouvière's sulcus and the variants of rouvière's sulcus which are catheghorized according to singh and prasad criteria. the following were considered secondary outcome: operative time expressed in minutes, biliary tract injuries according to stewart's classification and vascular injuries.

Eligibility criteria:
inclusion criteria: * patients undergoing videolaparoscopic cholecystectomy exclusion criteria: * if the lower face of the right hepatic lobe and the main elements of the biliary tract cannot be clearly analyzed patients will be excluded.

Keywords: prevalence rouvière's sulcus anatomical variations rouvière's sulcus
analgesic effect of etoricoxib (arcoxia®) 120mg during retinal laser photocoagulation

Conditions: Proliferative Diabetic Retinopathy

Summary: the study wants to show if the medication etoricoxib 120 mg have reduces the patients pain during the laser photocoagulation, for diabetic retinopathy.

to do so we compare two group of patients, randomized 1:1, one use the medication(etoricoxib) and other use placebo and they quantify the pain using the pain visual analogue scale

Eligibility criteria:
inclusion criteria: * patients with diabetic retinopathy that needs laser photocoagulation for the first time exclusion criteria: * younger than 17 * signs and symptoms of liver dysfunction or abnormal liver function tests * gastrointestinal diseases * pregnant women * edema * pre-existing cardiac insufficiency

Keywords: laser photocoagulation pain relief
management of initial bleeding/spotting associated with the levonorgestrel-releasing intrauterine system (mirena)

Conditions: Uterine Hemorrhage

Summary: the purpose of the study is to investigate if the study drugs (tranexamic acid or mefenamic acid) can control irregular bleeding during the first 3 months of using mirena. the study drugs tested are tested against placebo ("dummy medication not containing any active drug"). treatment period is followed by a one-month period when study drugs are not taken but mirena use is continued.


Eligibility criteria:
inclusion criteria: * signed and dated informed consent * healthy female subjects requesting contraception * age: 18 - 45 years inclusive * successful interval insertion of mirena * history of regular cyclic menstrual periods * normal or clinically insignificant cervical smear not requiring further follow up exclusion criteria: * pregnancy or lactation * climacteric symptoms prior to the screening visit * known or suspected clinically significant ovarian cysts, endometrial polyps, fibroids, or other genital organ pathology, that, in the opinion of the investigator, may interfere with the assessment of the bleeding profile during the study * undiagnosed abnormal genital bleeding * current or history of thrombembolic disease, or established risk factors for venous thromboembolism * current migraine, focal migraine with asymmetrical visual loss or other symptoms indicating transient cerebral ischemia, or exceptionally severe headaches * hypersensitivity to any ingredient of the investigational medicinal products or the non-investigational medicinal product * daily or frequent use of a nonsteroidal anti-inflammatory drug (nsaids) for any condition * not willing to use nonsteroidal anti-inflammatory drug (nsaids) medication as pain medication during the double blind treatment period

Keywords: uterine hemorrhage contraception contraceptive methods intrauterine devices mirena
preoperative cisplatin in early stage breast cancer

Conditions: Breast Cancer

Summary: the purpose of this study is to find out what effects the preoperative therapy cisplatin will have on patients with early stage estrogen receptor-negative (er-), progesterone receptor-negative (pr-), or her-2 negative breast cancer.

before starting treatment patients will undergo placement of a clip into the tumor bed so the surgeon can locate the site of the tumor at the time of surgery. patients will receive cisplatin intravenously once every three weeks for a total of 4 cycles or 12 weeks of treatment. after completion of cisplatin, patients will undergo surgery to remove any tumor that remains and to assess the tissue to see if tumor cells remain in the breast. patients may receive a second breast mri and biopsy 7-14 days after treatment begins to see whether we can identify tumors that will ultimately respond to cisplatin with a rapid evaluation. patients will receive study treatment for approximately 12 weeks unless unacceptable toxicity occurs. after surgery patients will receive standard adjuvant therapy based on discussion with their physician. follow-up progress will occur for several years.

Eligibility criteria:
inclusion criteria: * all tumors must be er-, pr- and her-2 negative. * age \> 18 years * ecog performance status of less than or equal to 1 * absolute neutrophil count (anc) \> 1,500/mm3 * hemoglobin \> 9mm/dl * platelets \> 100,000/mm3 * creatinine \< 1.5mg/dl * glucose \< 200mg/dl * bilirubin \< 1.5 x upper limit of normal (uln) * sgot \< 3.0 x uln exclusion criteria: * prior chemotherapy treatment * pregnant or breast-feeding women * history of serious illness, medical or psychiatric condition requiring medical management * uncontrolled infection * renal dysfunction * active or severe cardiovascular or pulmonary disease * peripheral neuropathy of any etiology that exceeds grade 1 * prior history of malignancy * uncontrolled diabetes

Keywords: cisplatin early stage breast cancer er negative breast cancer pr negative breast cancer her-2 negative breast cancer
global study looking at the combination of rad001 and sorafenib to treat patients with advanced hepatocellular carcinoma

Conditions: Hepatocellular Carcinoma

Summary: phase 1 evaluate the safety and tolerability of rad001 in combination with sorafenib in patients with advance hepatocellular cancer (hcc) and to determine the maximum tolerated dose (mtd) phase 2 to estimate the treatment effect as a measure of anti-tumor activity in terms of time to progression (ttp) of the combination of rad001 plus sorafenib, at the mtd, as compared to sorafenib alone


Eligibility criteria:
inclusion criteria: * advanced liver cancer * no previous systemic therapy for liver cancer * measurable disease on ct or mri * ecog 1 or less * child-pugh a exclusion criteria: * active bleeding during the last 30 days * known history of hiv seropositivity * any severe and/or uncontrolled medical conditions including other protocol-defined inclusion/exclusion criteria may apply

Keywords: hepatocellular carcinoma dose-finding study randomized trial medical treatment rad001 sorafenib advanced hepatocellular cancer (hcc)
comparison of laparoscopic cornuostomy and wedge resection for interstitial pregnancy

Conditions: Cornual Pregnancy

Summary: this retrospective study is to find out the best way to treat patient with cornual pregnancy in the aspect of further pregnancy outcome.

to find out the best way to treat patient with cornual pregnancy in the aspect of further pregnancy outcome, the investigators compared the outcomes of laparoscopic wedge resection (lwr) and laparoscopic cornuostomy (lc) by the retrospective chart review.

Eligibility criteria:
inclusion criteria: * all women with cornual pregnancy who were admitted to the department of obstetrics and gynecology of the far eastern memorial hospital for laparoscopic surgeries between january 2008 and june 2016 were enrolled exclusion criteria: * the person who was pregnant at the time of the operation * after receiving ivf course of treatment * patients with uterine horns undergoing open surgery
effectiveness of cognitive-affective behavior therapy for the treatment of somatization disorder

Conditions: Somatization Disorder

Summary: this study will examine the long-term effect of cognitive-affective behavior therapy on the physical symptoms, functioning, and health care utilization of people with somatization disorder.

somatization disorder is a syndrome characterized by the presence of multiple medically unexplained physical symptoms. it often results in substantial functional impairment and the need for extensive medical treatment. neither pharmacological nor psychosocial treatments for the disease have demonstrated clinical success. people with somatization disorder may benefit from a treatment that integrates emotion-centered strategies into cognitive behavioral therapy. the long-term effectiveness of this treatment has not been established, however. this study will examine the long-term effect of cognitive-affective behavior therapy on the physical symptoms, functioning, and health care utilization of people with somatization disorder. participants in this open-label study will be randomly assigned to receive either cognitive-affective behavior therapy (cabt) or standard medical care that is augmented by a psychiatric consultation. treatment will last 4 months. assessments of somatic symptomatology, functional impairment, and health care costs will occur at screening, baseline (1 to 2 weeks after screening), and 4, 10, and 16 months after baseline. the visits at 10 and 16 months post-baseline will assess specifically the long-term efficacy of the treatment.

Eligibility criteria:
inclusion criteria: * meets dsm-iv criteria for somatization disorder * available for follow-up over the ensuing 18 months * english-speaking exclusion criteria: * meets dsm-iv criteria for a psychotic disorder, organic brain syndrome, or psychoactive substance dependence (other psychiatric comorbidity is not exclusionary) * active suicidal ideation * unstable major medical condition * plans to engage in additional psychotherapy during the first 6 months after enrollment * current use of any medication that has not been stabilized for the previous 2 months

Keywords: cognitive behavior therapy treatment outcome health care utilization somatization disorder somatoform disorder
hpv multilevel intervention strategies targeting immunization in community settings (hpv mistics)

Conditions: Human Papilloma Virus (HPV) Vaccine

Summary: this intervention study will use parent-, provider-, and health center-level strategies to promote hpv vaccination among 11-17 year olds receiving care in 8 community health centers in florida, will explore factors related to the intervention effect, and will explore implementation outcomes of the intervention.

the goals of this multi-level intervention study are to: 1) test whether hpv mistics intervention increases human papillomavirus (hpv) vaccine initiation and completion rates among 11-17-year-old adolescents in 8 health choice network-affiliated community health centers in florida. 2) explore other factors related to the intervention effect. 3) explore implementation outcomes (i.e., reach, adoption, implementation, maintenance, and sustainability) and identify implementation barriers and facilitators with a focus on equity. the study will use parent-, provider-, and health center-level strategies to promote hpv vaccination.

Eligibility criteria:
inclusion criteria: * for staff: * 18 years of age or older * working within the participating federally qualified health center system * able to read, write and speak english * for providers: * 18 years of age or older * working within the participating federally qualified health center system * interacting with parents of adolescents ages 11-17 * able to read, write and speak english * for parents: * parent of 11-17 year old child that has received care within the prior two months at one of the participating federally qualified health centers * whose child has not initiated or completed the hpv vaccine series at the time of their last visit * able to read, write and speak english or spanish, or haitian creole

Keywords: human papillomavirus vaccination multi-level intervention community health centers behavioral
evaluation of vitrectomy with ilm peeling in myopic macular hole with only posterior retinal detachment

Conditions: Retinal Detachment

Summary: retinal detachment (rd) resulting from the macular hole (mh), also known as mh-induced rd (mhrd), most commonly occurs in eyes with high myopia and results in irreversible visual disorders. although ilm peeling for mhrd reportedly achieves a high retinal reattachment rate that ranges from 70% to 100%, the mh closure rate is relatively low, ranging from 10% to 70%.


Eligibility criteria:
inclusion criteria: * patients with high myopia (a spherical equivalent refractive error of at least -6.0 diopters (d) and an axial length of at least 26.5 mm). * macular hole and only posterior retinal detachment exclusion criteria: * other causes of rd * patients with a history of trauma, choroidal neovascularization, coexistence with a peripheral retinal break or proliferative vitreoretinopathy * history of any vitreoretinal surgery prior to mhrd and less than 36 months of follow-up after the surgery